---
title: "Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 \"Pan-Kras Inhibitor\" Approved By FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282117061.md"
datetime: "2026-04-09T01:30:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282117061.md)
  - [en](https://longbridge.com/en/news/282117061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282117061.md)
---

# Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 "Pan-Kras Inhibitor" Approved By FDA

April 9 (Reuters) - Sino Biopharmaceutical Ltd (1177.HK) : \* APPLICATION FOR CLINICAL TRIAL ON TQB3205 "PAN-KRAS INHIBITOR" APPROVED BY FDA Further company coverage: (1177.HK)

### Related Stocks

- [44080.HK](https://longbridge.com/en/quote/44080.HK.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [NAVB.US](https://longbridge.com/en/quote/NAVB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Celcuity Reports Positive Phase 3 Results for Gedatolisib](https://longbridge.com/en/news/284945567.md)
- [Palisade Bio reports phase 1a/b data showing colon‑targeted exposure](https://longbridge.com/en/news/285211825.md)
- [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md)
- [Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals](https://longbridge.com/en/news/284275878.md)
- [18:00 ETZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent](https://longbridge.com/en/news/285274912.md)